Skip to main content
Erschienen in: BMC Pediatrics 1/2022

Open Access 01.12.2022 | Research

The quality of life in children with spinal muscular atrophy: a case–control study

verfasst von: Gholamreza Zamani, Mahmoud Reza Ashrafi, Homa Ghabeli, Masood Ghahvechi Akbari, Mahmoud Mohammadi, Reza Shervin Badv, Sareh Hosseinpour, Roya Haghighi, Elham Pourbakhtyaran, Nahid Khosroshahi, Morteza Heidari

Erschienen in: BMC Pediatrics | Ausgabe 1/2022

Abstract

Objectives

This study aimed to analyze the health-related quality of life (HRQoL) of patients with spinal muscular atrophy (SMA) based on the type of SMA, demographic and clinical features and compare HRQoL of these patients with a matched healthy control group. 

Methods

This was a case–control study of Patients with SMA in Iran. Sixty-six patients with SMA type II and III aged 8–18 years and also 264 healthy age, sex, and socio-economic matched individuals were enrolled. To assess the quality of life, we used the Persian version of the KIDSCREEN-27.

Results

The health-related quality of life between children with type II and type III SMA was not significant in all 5 subscales. However, HRQoL in healthy children was significantly higher than in SMA children in all 5 subscales.

Conclusion

The quality of life in children with SMA was lower than the healthy control group in all subscales, and physical well-being and psychosocial aspects are the main domains of life impaired by SMA disease. However, no significant difference between the quality of life in children with SMA type II and type III was observed. 
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
SMA
Spinal Muscular Atrophy
HRQoL
Health-related quality of life
QoL
Quality of life
DMD
Duchenne muscular dystrophy

Background

Spinal muscular atrophy (SMA) is an inherited autosomal recessive disease [1] characterized by degeneration of alpha motor neurons of the spinal cord, resulting in generalized muscle weakness and atrophy [2, 3]. SMA is the second fatal neuromuscular disease after cystic fibrosis, with an estimated incidence of about one in 6000–10,000 live births and a carrier frequency of 1/40–1/60 [4, 5].
The clinical manifestations of SMA are divided into three major categories in childhood according to the age of onset and motor function achieved [6]. The spectrum of muscle weakness in SMA ranges from extremely compromised neonates to minimally affected adults with late-onset [6, 7]. Generally, the severe form of SMA is type I which is manifested by muscle weakness and hypotonia. Children who suffer from SMA type II are able to sit, but they need aid for standing or walking; and finally, the mild form of SMA is type III who learn to walk unaided [5, 8].
Since these patients will need nursing support due to losing their motor function or respiratory compromise or nutritional problems in advanced stages [2, 9], they would be dependent on others and therefore their quality of life is touched. Since the severity and timing of these complications vary according to the type of disease [1, 10], this factor can also affect the extent of patient dependency on others. In addition, factors such as the socio-economic status of patients and the level of their access to appropriate health care can have a significant effect on their quality of life [11].
Health-related quality of life (HRQoL) is a multidimensional framework that generally evaluates social, psychological, and physical functioning of a patient [12]. Although HRQoL tools are described according to individual perspective of one’s life status along with personal judgment over patient's health and disease and also norms of the community in where they live [13], various studies indicate these tools are reliable in the assessment of standard cares that patients receive [14, 15]. There are controversy results in subscales of the quality of life in various studies and most of them do not report their results according to SMA type and demographic data [1620]. In the current research, we aimed to answer the following questions:
First, Does HRQoL of SMA children differ from that of a matched healthy control group? Second, Does HRQoL of children with SMA vary according to SMA type? Third, Does HRQoL of SMA children differ according to demographic and clinical features?

Methods

Participants

We conducted a case–control study on 66 patients diagnosed with SMA aged 8–18 years who were referred to the pediatric neurology department of Tehran University of Medical Sciences where SMA patients were being monitored. We considered this age group because the patients and their parents were both adapted to the disease. We also selected 264 healthy age, sex, and socio-economic matched individuals and their parents from the same school in which patients attended as controls. The inclusion criteria were age range of 8–18 years, SMA diagnosis was done based on clinical manifestations, clinical fitures,electrodiagnosis and confirmed by a genetic test. Clinical features such as respiratory and gastrointestinal diseases were diagnosed through medical examination and obtained retrospectively from patients’ medical records. The exclusion criteria were mental disorders, hearing, or visual impairments, and or any congenital disorder. This study was approved by the ethical committee of Tehran University of Medical Sciences (IR.TUMS.CHMC.REC.1400.063), furthermore written informed consent was taken from all participants’ legal guardians collaborating in this study.

Assessment tools and data collection

To assess the quality of life, we used the Persian version of the KIDSCREEN-27. All versions of this questionnaire, including child and parent’s versions that had been validated for Iranian population aged 8–18 years old [21]. Since mothers usually spend much more time with kids [22], the parent's version of KIDSCREEN-27 was completed mostly by mothers. In our study, the parents and children both completed the questionnaire at home. This questionnaire consists of 5 categories, including physical well-being (5 items), psychological well-being (7 items), parent relationship (7 items), social support and peers (4 items), social environment (4 items). The recall period lasted two weeks, and the higher score revealed a better quality of life.

Statistical analysis

We described the quantitative data using mean and standard deviation (SD) and the categorical data using frequency and percentage. Moreover, we checked the normality assumption of data prior to the analysis, then we compared the health-related quality of life between the SMA types (type II and type III) and also between the case and control groups, using independent-samples T test. The health-related quality of life was also compared according to demographic and clinical features, listed in Table 1. The P-value of less than 0.05 was considered significant. All analyses were performed using SPSS version 24.
Table 1
Comparing the quality of life in SMA children (n = 66) based on demographic and clinical features
Variables
Physical well-being
Psychological well-being
Parent relationship
Social support and peers
Social environment
Gender
 Boys
12.9 ± 2.3
20.6 ± 5.7
24.9 ± 5.0
12.1 ± 4.0
13.0 ± 4.3 *
 Girls
12.2 ± 2.1
19.2 ± 5.2
24.8 ± 4.8
13.0 ± 3.6
15.2 ± 3.8
Eductaion of mother
 ≤ 12
12.1 ± 2.1*
19.1 ± 5.1 *
23.8 ± 5.0 *
12.1 ± 4.0
13.9 ± 4.1
 > 12
13.8 ± 2.1
22.2 ± 6.0
27.6 ± 3.4
13.7 ± 3.1
14.8 ± 3.4
Eductaion of father
 ≤ 12
12.3 ± 2.4
18.5 ± 4.9 *
23.4 ± 4.7 *
11.6 ± 4.0 *
13.2 ± 4.3 *
 > 12
12.9 ± 1.9
21.8 ± 5.6
26.7 ± 4.5
13.8 ± 3.1
15.4 ± 3.1
Number of children
 <  = 2
12.7 ± 2.3
20.0 ± 5.1
25.7 ± 4.8 *
12.4 ± 3.8
13.8 ± 4.0
 > 2
12.3 ± 2.2
19.6 ± 6.1
22.9 ± 4.7
12.7 ± 3.8
14.8 ± 3.8
Access to medical facilities
 Yes
12.6 ± 2.3
21.1 ± 5.6 *
24.6 ± 5.1
13.0 ± 3.7
14.3 ± 4.0
 No
12.4 ± 2.1
17.2 ± 4.1
25.3 ± 4.6
11.5 ± 3.9
13.8 ± 4.0
Dependence to wheelchair
 No
14.4 ± 2.1 *
20.7 ± 4.1
27.1 ± 3.4 *
12.3 ± 3.7
13.9 ± 3.0
 Yes
12.2 ± 2.1
19.7 ± 5.7
24.3 ± 5.0
12.6 ± 3.8
14.2 ± 4.1
Respiratory diseases
 Yes
12.0 ± 2.0
20.1 ± 4.7
23.5 ± 5.7 *
12.5 ± 5.3
13.6 ± 4.7
 No
12.7 ± 2.3
19.8 ± 5.6
25.1 ± 4.7
12.5 ± 3.5
14.2 ± 3.8
GI diseases
 Yes
11.6 ± 1.5 *
18.4 ± 4.3
24.1 ± 5.4
10.7 ± 4.7 *
13.5 ± 4.9
 No
12.9 ± 2.4
20.5 ± 5.8
25.1 ± 4.7
13.2 ± 3.2
14.4 ± 3.6
History of mood disorders
 Yes
11.9 ± 2.2 *
17.1 ± 5.7 *
23.2 ± 4.9 *
12.4 ± 4.0
14.1 ± 3.7
 No
13.0 ± 2.1
21.7 ± 4.5
25.8 ± 4.6
12.6 ± 3.7
14.2 ± 4.1
GI gastrointestinal
*P-value less than 0.05

Results

Among 66 children with SMA, there were 12 (35.3%) boys and 22 (64.7%) girls with SMA type II, and there were 19 (59.4%) boys and 13 girls (40.6%) with SMA type III. The mean (SD) age of children with type II SMA was 11.3 (3.5), and it was 15.5 (3.4) in children with type III SMA. Based on SMA type, there was no significant difference between the age of boys and girls.
Table 2 indicates that the health-related quality of life between children with type II and type III SMA is not significant in all 5 subscales, both children's and parent's perspectives.
Table 3 demonstrates that the health-related quality of life in healthy children is significantly higher than in SMA children in all 5 subscales, both children's and parents’ perspective. The highest mean difference was observed in physical and psychological well-being. Moreover, no significant difference was detected between children's and parents’ perspectives in reporting health-related quality of life.
Table 2
Comparing the quality of life in children with type II and type III SMA
 
Type II SMA (n = 34)
Type III SMA (n = 32)
P-value
Child
 Physical well-being
12.1 ± 2.1
13.0 ± 2.3
0.09
 Psychological well-being
19.3 ± 3.0
19.9 ± 2.8
0.42
 Parent relationship
24.3 ± 4.9
25.3 ± 4.8
0.43
 Social support and peers
12.3 ± 3.9
12.7 ± 3.7
0.67
 Social environment
14.1 ± 4.8
14.2 ± 2.8
0.89
Parent
 Physical well-being
12.6 ± 2.1
12.3 ± 2.5
0.67
 Psychological well-being
21.2 ± 2.5
20.06 ± 2.7
0.30
 Parent relationship
23.7 ± 5.4
24.4 ± 5.2
0.59
 Social support and peers
11.4 ± 4.2
12.6 ± 3.6
0.22
 Social environment
13.4 ± 4.8
13.9 ± 3.1
0.62
Table 3
Comparing the quality of life in SMA children with that of a matched healthy control group
 
Case group (n = 66)
Control group (n = 264)
 
Mean ± SD
Mean ± SD
p-value
Child
 Physical well-being
12.6 ± 2.2
19.6 ± 3.9
 < 0.001
 Psychological well-being
19.6 ± 2.9
25.6 ± 5.7
 < 0.001
 Parent relationship
24.8 ± 4.9
26.9 ± 5.6
0.005
 Social support and peers
12.5 ± 3.8
14.5 ± 3.3
 < 0.001
 Social environment
14.1 ± 3.9
15.4 ± 3.1
0.004
Parent
 Physical well-being
12.5 ± 2.3
19.4 ± 3.8
 < 0.001
 Psychological well-being
20.9 ± 2.6
25.9 ± 5.1
 < 0.001
 Parent relationship
24.7 ± 5.3
27.1 ± 5.0
 < 0.001
 Social support and peers
12.1 ± 3.9
13.7 ± 3.2
 < 0.001
 Social environment
13.6 ± 4.1
15.4 ± 2.9
 < 0.001
The quality of life in children with SMA was varied according to demographic and clinical features. SMA children whose mothers had less than 12 years of education and also SMA children with history of mood disorders had significant lower score in Physical and psychosocial well-being, and also parent relationships. Low education of fathers also associated with all subscales of the SMA children’s quality of life except physical well-being subscale. Each of demographic and clinical variables is associated with a different subscale of quality of life, details have been shown in Table 1.

Discussion

In this case–control study, the quality of life was compared between SMA children and a healthy control group, between type II and type III SMA, and also the quality of life was compared according to demographic and clinical features in children with SMA.
The current study indicated that the quality of life in children with SMA varies from that in the matched healthy control group in all subscales. It is important to note that two subscales of quality of life, including physical and psychosocial well-being, were more affected in SMA patients. A systematic review has recently indicated that all subscales are affected by SMA to some degree, however physical well-being is the main domain of life impaired by SMA [23]. Due to the similarity of locomotion impairment on quality of life in neuromuscular disorders, the most common childhood neuromuscular disorder, Duchenne muscular dystrophy (DMD), was considered in the literature review [24]. Most case–control studies have been indicating that the quality of life varies in all subscales [1618, 25]; however, Zamani et al. [22] observed the low scores in just two subscales, including physical well-being and peers. Opstal et al. [26] observed the low score only in the physical well-being subscale. The differences across studies may be explained by the small sample size and the type of questionnaire used [18], according to a systematic review conducted by Landfeldt et al. [24], 40% of the studies had been done with a small sample size (less than 35).
We did not find any significant difference between the quality of life in children with SMA type II and type III. Since studies have evaluated QoL by different tools [24] and most of them do not report their results according to SMA type, demographic data, or functional ability [19, 20, 2729], it is hard to draw an appropriate conclusion over the observed differences. However, an inverse association has been suggested by some data [23].
This study showed that girls with SMA had a better score in the social environment subscale in compare to the boys. It may be due to different interests and styles of life in different genders in this age group in Iranian children. However, planning for the promotion of this aspect for the both genders to improve their participation in social activities, including supportive consultation, and providing recreational and educational facilities to change the patient's attitudes is recommended [22].

Conclusion

The current study declares that the quality of life in children with SMA varies in comparison with healthy control group in all subscales. However physical well-being and psychosocial aspects are the main domains of life impaired by SMA disease. We did not find any significant difference between the quality of life in children with SMA type II and type III. Furthermore, better social score in girls is seen in comparison with boys with SMA patients that may be due to different interests and styles of life in different genders in this age group in Iranian children. At the time of doing this study none of the patients had access to advanced treatments, for sure the QoL after access to new treatment and the multidisciplinary clinic would differ. So, a new study to evaluate and compare the issue of QoL after access to treatment in these patients is recommended.

Strengths and limitations

Compared to many studies, the strength of our study was comparing the quality of life according to SMA type and some demographic and clinical features. Moreover, the design of our study was case control, which provides more reliable results compared to cross-sectional studies. However, we did not have adequate sample size to analyze our data based on functional status (non-sitter, sitter, walkers).

Acknowledgment

The authors express the gratitude to children with SMA and their parents in addition to Iranian SMA and Muscular dystrophy association.

Declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of 1964 Helsinki declaration. This study was approved by the ethical committee of Tehran University of Medical Sciences (IR.TUMS.CHMC.REC.1400.063), furthermore written informed consent was taken from all participants’ legal guardians collaborating in this study.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Lunn MR, Wang CH. Spinal muscular atrophy. The Lancet. 2008;371(9630):2120–33.CrossRef Lunn MR, Wang CH. Spinal muscular atrophy. The Lancet. 2008;371(9630):2120–33.CrossRef
2.
Zurück zum Zitat D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):1–10. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):1–10.
3.
Zurück zum Zitat Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–46.CrossRef Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–46.CrossRef
4.
Zurück zum Zitat Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301–7.CrossRef Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301–7.CrossRef
5.
Zurück zum Zitat Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152(7):1608–16.CrossRef Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152(7):1608–16.CrossRef
6.
Zurück zum Zitat Mendonça RH, Rocha AJ, Lozano-Arango A, Diaz AB, Castiglioni C, Silva AM, et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol. 2019;86(3):458–62.CrossRef Mendonça RH, Rocha AJ, Lozano-Arango A, Diaz AB, Castiglioni C, Silva AM, et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol. 2019;86(3):458–62.CrossRef
7.
Zurück zum Zitat Talbot K, Tizzano E. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24(9):529–33.CrossRef Talbot K, Tizzano E. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24(9):529–33.CrossRef
8.
Zurück zum Zitat Pera MC, Coratti G, Berti B, D’Amico A, Sframeli M, Albamonte E, et al. Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? PLoS ONE. 2020;15(3):e0230677.CrossRef Pera MC, Coratti G, Berti B, D’Amico A, Sframeli M, Albamonte E, et al. Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? PLoS ONE. 2020;15(3):e0230677.CrossRef
9.
Zurück zum Zitat Messina S, Pane M, De Rose P, Vasta I, Sorleti D, Aloysius A, et al. Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscul Disord. 2008;18(5):389–93.CrossRef Messina S, Pane M, De Rose P, Vasta I, Sorleti D, Aloysius A, et al. Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscul Disord. 2008;18(5):389–93.CrossRef
10.
Zurück zum Zitat Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021;37:100878. Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021;37:100878.
11.
Zurück zum Zitat Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E, et al. The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe. Int J Environ Res Public Health. 2020;17(16):5640.CrossRef Peña-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E, et al. The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe. Int J Environ Res Public Health. 2020;17(16):5640.CrossRef
12.
Zurück zum Zitat Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84(3):205–11.CrossRef Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84(3):205–11.CrossRef
13.
Zurück zum Zitat Boström K, Ahlström G. Quality of life in patients with muscular dystrophy and their next of kin. Int J Rehabil Res. 2005;28(2):103–9.CrossRef Boström K, Ahlström G. Quality of life in patients with muscular dystrophy and their next of kin. Int J Rehabil Res. 2005;28(2):103–9.CrossRef
14.
Zurück zum Zitat Gibson B. Long-term ventilation for patients with Duchenne muscular dystrophy: physicians’ beliefs and practices. Chest. 2001;119(3):940–6. Gibson B. Long-term ventilation for patients with Duchenne muscular dystrophy: physicians’ beliefs and practices. Chest. 2001;119(3):940–6.
15.
Zurück zum Zitat Grootenhuis MA, De Boone J, Van der Kooi AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes. 2007;5(1):1–8.CrossRef Grootenhuis MA, De Boone J, Van der Kooi AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes. 2007;5(1):1–8.CrossRef
16.
Zurück zum Zitat Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, et al. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011;26(6):707–13.CrossRef Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, et al. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011;26(6):707–13.CrossRef
17.
Zurück zum Zitat Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012;10(1):1–9.CrossRef Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012;10(1):1–9.CrossRef
18.
Zurück zum Zitat Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, et al. The PedsQL™ in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of life inventory neuromuscular module and generic core scales. J Clin Neuromuscul Dis. 2010;11(3):97–109.CrossRef Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, et al. The PedsQL™ in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of life inventory neuromuscular module and generic core scales. J Clin Neuromuscul Dis. 2010;11(3):97–109.CrossRef
19.
Zurück zum Zitat de Oliveira CM, Alexandra P. Self-reported quality of life has no correlation with functional status in children and adolescents with spinal muscular atrophy. Eur J Paediatr Neurol. 2011;15(1):36–9.CrossRef de Oliveira CM, Alexandra P. Self-reported quality of life has no correlation with functional status in children and adolescents with spinal muscular atrophy. Eur J Paediatr Neurol. 2011;15(1):36–9.CrossRef
20.
Zurück zum Zitat Kruitwagen-Van Reenen ET, Wadman RI, Visser-Meily JM, van den Berg LH, Schröder C, van der Pol WL. Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle Nerve. 2016;54(5):850–5.CrossRef Kruitwagen-Van Reenen ET, Wadman RI, Visser-Meily JM, van den Berg LH, Schröder C, van der Pol WL. Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle Nerve. 2016;54(5):850–5.CrossRef
21.
Zurück zum Zitat Jafari P, Bagheri Z, Safe M. Item and response-category functioning of the Persian version of the KIDSCREEN-27: Rasch partial credit model. Health Qual Life Outcomes. 2012;10(1):1–6.CrossRef Jafari P, Bagheri Z, Safe M. Item and response-category functioning of the Persian version of the KIDSCREEN-27: Rasch partial credit model. Health Qual Life Outcomes. 2012;10(1):1–6.CrossRef
22.
Zurück zum Zitat Zamani G, Heidari M, Malamiri RA, Ashrafi MR, Mohammadi M, Badv RS, et al. The quality of life in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(7):423–7.CrossRef Zamani G, Heidari M, Malamiri RA, Ashrafi MR, Mohammadi M, Badv RS, et al. The quality of life in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(7):423–7.CrossRef
23.
Zurück zum Zitat Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmueller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol. 2019;23(3):347–56.CrossRef Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmueller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol. 2019;23(3):347–56.CrossRef
24.
Zurück zum Zitat Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27(12):3087–94.CrossRef Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27(12):3087–94.CrossRef
25.
Zurück zum Zitat Elsenbruch S, Schmid J, Lutz S, Geers B, Schara U. Self-reported quality of life and depressive symptoms in children, adolescents, and adults with Duchenne muscular dystrophy: a cross-sectional survey study. Neuropediatrics. 2013;44(05):257–64.CrossRef Elsenbruch S, Schmid J, Lutz S, Geers B, Schara U. Self-reported quality of life and depressive symptoms in children, adolescents, and adults with Duchenne muscular dystrophy: a cross-sectional survey study. Neuropediatrics. 2013;44(05):257–64.CrossRef
26.
Zurück zum Zitat Opstal SHV, Jansen M, van Alfen N, de Groot IJ. Health-related quality of life and its relation to disease severity in boys with Duchenne muscular dystrophy: satisfied boys, worrying parents-a case-control study. J Child Neurol. 2014;29(11):1486–95.CrossRef Opstal SHV, Jansen M, van Alfen N, de Groot IJ. Health-related quality of life and its relation to disease severity in boys with Duchenne muscular dystrophy: satisfied boys, worrying parents-a case-control study. J Child Neurol. 2014;29(11):1486–95.CrossRef
27.
Zurück zum Zitat Abresch RT, Carter GT, Jensen MP, Kilmer DD. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Med®. 2002;19(1):39–48.CrossRef Abresch RT, Carter GT, Jensen MP, Kilmer DD. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Med®. 2002;19(1):39–48.CrossRef
28.
Zurück zum Zitat Kocova H, Dvorackova O, Vondracek P, Haberlova J. Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatr Neurol. 2014;50(6):591–4.CrossRef Kocova H, Dvorackova O, Vondracek P, Haberlova J. Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatr Neurol. 2014;50(6):591–4.CrossRef
29.
Zurück zum Zitat López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):1–7.CrossRef López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):1–7.CrossRef
Metadaten
Titel
The quality of life in children with spinal muscular atrophy: a case–control study
verfasst von
Gholamreza Zamani
Mahmoud Reza Ashrafi
Homa Ghabeli
Masood Ghahvechi Akbari
Mahmoud Mohammadi
Reza Shervin Badv
Sareh Hosseinpour
Roya Haghighi
Elham Pourbakhtyaran
Nahid Khosroshahi
Morteza Heidari
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Pediatrics / Ausgabe 1/2022
Elektronische ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-022-03751-y

Weitere Artikel der Ausgabe 1/2022

BMC Pediatrics 1/2022 Zur Ausgabe

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.